The BED was established at 60 mg/m2 daily for 5 days and the drug was well tolerated by both MDS and AML patients up to 90 mg/m2 daily for 5 days. Two patients had dose limiting toxicities (DLT's), mainly febrile neutropenia, thrombocytopenia and sepsis, out of 12 patients treated at the highest dose of 125 mg/m2 daily for 5 days.
The dose expansion part of the study is ongoing, and patients with AML (first-line elderly; or relapsed/refractory) and first line MDS are being randomized to either 60 or 90 mg/m2 daily for 5 days. A third arm was added to investigate the dose of 60 mg/m2 daily for 10 days in relapsed/refractory AML.
"This is the only new hypomethylating agent now in advanced clinical development, and we are excited by the differentiated PK profile and the favorable safety profile so far in this study. We are looking forward to the results of the Phase 2 dose expansion part of the trial that is now ongoing," commented Dr. Hagop Kantarjian.
About the StudyThe SGI-110 study enrolled 78 patients (64 AML, 14 MDS), in the dose escalation part of this randomized Phase 1/2 first-in-human trial with 44 patients receiving drug daily for 5 days (dailyx5 regimen) and 34 patients receiving drug once weekly for 3 consecutive weeks (weeklyx3 regimen). Median age was 69 years, and 87% had ECOG PS of 0-1. Median number of prior regimens was 3 (range 1-9), 63% of patients had prior hypomethylation agent (HMA) treatment (55% of AML patients, and 100% of MDS patients). A copy of the 2012 ASH presentation, "Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML," will be available on the Astex Pharmaceuticals website, www.astx.com , in the pipeline, presentations and publications section. About Astex Pharmaceuticals Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.